Dignity Health;The Translational Genomics Research Institute
发明人:
Timothy G. Whitsett, JR.,Landon J. Inge
申请号：
US16565605
公开号：
US20200000808A1
申请日:
2019.09.10
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Embodiments of the invention provide a method of treating cancer, the method comprising providing a subject having cancer cells, and contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising the steps of: (a) receiving a sample of the cancer cells from the subject； (b) determining if at least a portion of the sample of the cancer cells is LKB1 deficient； and (c) contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising contacting the cancer cells with a therapeutically effective amount of a Wee1 inhibitor and a therapeutically effective amount of a second pharmaceutical composition. Embodiments of the invention also provide a method of prognosing or determining the severity of cancer in a subject comprising (a) determining the presence or absence of LKB1 in the cancer cells of the subject； and (b) prognosing the severity of cancer based on the presence of LKB1 deficiency in the cancer cells of the subject.
